Skip to main navigation Skip to search Skip to main content

Prospects for Leveraging the Microbiota as Medicine for Hypertension

  • David J. Durgan
  • , Jasenka Zubcevic
  • , Matam Vijay-Kumar
  • , Tao Yang
  • , Ishan Manandhar
  • , Sachin Aryal
  • , Rikeish R. Muralitharan
  • , Hong Bao Li
  • , Ying Li
  • , Justine M. Abais-Battad
  • , Jennifer L. Pluznick
  • , Dominik N. Muller
  • , Francine Z. Marques
  • , Bina Joe

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

In 1924, the distinguished Dutch physiologist Willem Einthoven was awarded the Nobel Prize in Physiology or Medicine for his research and invention of the ECG. Coincidentally, the same year marked the birth of the American Heart Association (AHA), whose central mission, as the name indicates, was also focused on heart health. By then, the term essential hypertension (essentielle hypertonie) was already coined by Eberhard Frank to describe elevated blood pressure (BP).1 However, at that time, the relationships between the heart and essential hypertension were murky.2 Fast-forward to 2024, and as we celebrate the centennial year of the AHA, it is clear that essential hypertension persists as the single most significant risk factor for heart diseases, which are the major contributors to human morbidity and mortality. Therefore, finding solutions to curb essential hypertension is central to achieving the mission of the AHA, which is to be a relentless force for a world of longer, healthier lives.
Original languageEnglish
Pages (from-to)951-963
Number of pages13
JournalHypertension
Volume81
Issue number5
DOIs
Publication statusPublished - 1 May 2024

Keywords

  • blood pressure
  • essential hypertension
  • heart diseases
  • inventions
  • microbiota

Cite this